NCT06139055View on ClinicalTrials.gov

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

GSBR-1290 (Capsule/Tablet)

Participants will receive GSBR-1290 oral capsules or tablets.

DRUG

GSBR-1290

Participants will receive GSBR-1290 oral tablets.

DRUG

Placebo

Participants will receive matching-placebo oral tablets.

DRUG

Placebo (Capsule/Tablet)

Participants will receive matching-placebo oral capsules or tablets.

Trial Locations (3)

21225

Parexel Baltimore Early Phase Clinical Unit, Baltimore

33014

ERG Clinical (Clinical Pharmacology of Miami - CPMI), Miami

33131

Syneos Miami Site, Miami

All Listed Sponsors
lead

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

INDUSTRY

NCT06139055 - A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants | Biotech Hunter | Biotech Hunter